How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,587 results for

Cerebrovascular Accident Risk in Women

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women

the incidence of vertebral fractures. The common adverse drug reaction is slight increase in hot flash and leg cramps, and the most serious adverse drug reaction is venous thromboembolism. Past research has found that raloxifene can reduce the risk of decline in memory and attention, and taking raloxifene helps sleep. Current research suggests that as an adjuvant therapy, it can improve symptoms of menopausal women with schizophrenia (emotional symptoms, memory, information processing and storage (...) disease thrombotic disease Estrogen dependent tumor Hyperthyreosis Severe cardiac dysfunction or renal disease Diabetes mellitus Abnormal uterine bleeding or cerebrovascular accident Hormone replacement therapy using mood stabilizer Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2018 Clinical Trials

22. Aortic Arch Width and Cardiovascular Disease in Men and Women in the Community (PubMed)

) examinations. The primary CVD outcome was a composite of myocardial infarction, coronary insufficiency, cerebrovascular accident, first hospitalization for heart failure, or CVD death. Cox proportional hazards models were used to estimate hazard ratio of high AAW on time-to-incident CVD after adjustment for Framingham risk factors and CAC. Net reclassification improvement was used to assess the effect of adding AAW to the baseline Framingham risk factor+CAC model. A total of 2826 participants (aged 51±11 (...) Aortic Arch Width and Cardiovascular Disease in Men and Women in the Community We sought to determine whether increased aortic arch width (AAW) adds to standard Framingham risk factors and coronary artery calcium (CAC) for prediction of incident adverse cardiovascular disease (CVD) events in community-dwelling adults.A total of 3026 Framingham Heart Study Offspring and Third Generation cohort participants underwent noncontrast multidetector computed tomography from 2002 to 2005 to quantify CAC

Full Text available with Trip Pro

2018 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

23. A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

on the mean value of the triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation or Torsade de Pointes. any of the following within 6 months of inclusion: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE Grade <2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack (...) A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2018 Clinical Trials

24. Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer

stenotic valve disease. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade ≥2, cerebrovascular accident, or transient ischaemic attack. Uncontrolled hypertension. Hypertensive patients may be eligible but blood pressure must be adequately controlled at baseline. Patients may be re-screened (...) Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2018 Clinical Trials

25. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. (PubMed)

accident or transient ischemic attack, renal insufficiency or failure, venous thromboembolism, pulmonary embolism, and operative complications.Among 120 patients (mean age; 71 [SD, 10] years, 37 women [31%]) included in the study, combined CABG and valve repair or replacement surgery comprised 72% of procedures and had a mean (SD) cardiopulmonary bypass time of 200 minutes (83) minutes. For the primary outcome, median blood loss in the fibrinogen group was 50 mL (interquartile range [IQR], 29-100 mL (...) Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. Fibrinogen concentrate might partly restore coagulation defects and reduce intraoperative bleeding.To determine whether fibrinogen concentrate infusion dosed to achieve a plasma fibrinogen level of 2.5 g/L in high-risk cardiac surgery patients with intraoperative bleeding reduces intraoperative blood loss.A randomized, placebo

Full Text available with Trip Pro

2017 JAMA

26. The Management of Dyslipidemia for Cardiovascular Risk Reduction (Lipids)

-to-severe systolic chronic heart failure (CHF), a limited life expectancy (LE) ( age 35 and women > age 45, including a lipid profile and a risk calculation. Strong For 2 A We recommend against routine screening for dyslipidemia outside of the context of a cardiovascular risk assessment. Strong Against 3 D For risk calculation, we suggest a 10-year risk calculator. Weak For 4 C We suggest that patients being considered for statin therapy be assessed for other CVD risk factors, including, but not limited (...) prevention. Comparative research studies are needed to clarify the role of statin dose in primary prevention. Assessment of Cardiovascular Risk and Pharmacotherapy for Primary Prevention (Patients without a history of ASCVD or ACS) Recommendations 1. We recommend CVD risk screening for men > age 35 and women > age 45, including a lipid profile and a risk calculation. Strong For 2. We recommend against routine screening for dyslipidemia outside of the context of a cardiovascular risk assessment. Strong

2014 VA/DoD Clinical Practice Guidelines

27. Consensus on women?s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

with PCOS (20). Conclusions(Agreement) Both amenorrheic and oligomenorrheic women may occa- sionally ovulate (level B). Menstrual cycles in women with PCOS may become more regular later in life (level B). Irregular menses are associated with increased metabolic risk (level B). The greater the menstrual irregularity, the more severe the PCOS phenotype (level B). Disagreement The time needed before regular menstrual cycles occur in young women. The extent to which irregular menses (especially amenor (...) ). A Cochrane review, based on limited evidence, concluded that OCP use does not increasemetabolicrisk(22).Findingsfromafewsmallstudies suggest that insulin resistance worsens during the natural courseofPCOS,butlong-termOCPuseeitherdoesnotchange orimprovescardiometabolicriskparameters,includinginsu- lin resistance, lipoprotein pro?le, and possibly body fat distribution. Conclusions(Agreement) Overall, the bene?ts of OCPs outweigh the risks in most patients with PCOS (level B). Women with PCOS are more

2012 Society for Assisted Reproductive Technology

28. Period prevalence, risk factors and consequent injuries of falling among the Saudi elderly living in Riyadh, Saudi Arabia: a cross-sectional study. (PubMed)

to fall than those who did not. Participants who mentioned 'not having stressors were associated with less frequent falls (aOR 0.62; 95% CI 0.39 to 0.97). Cerebrovascular accidents were strongly associated with falls with an estimated OR of 2.75 (95% CI 1.18 to 6.43). Moreover, osteoporosis, poor vision and back pain were found to be predictors for falls among the elderly.49.9% of elderly Saudis had experienced one or more falls during a 12-month period. Several preventable risk factors could (...) . In addition, this study described the most common risk factors and consequent injuries of falls.A cross-sectional survey was carried out in Riyadh, using a convenient sampling. The targeted population were Saudi citizens who were 60 years or above. Over a 6-month period, 1182 individuals were sampled (545 men and 637 women).The 1-year prevalence of falling among old Saudis (>=60 years) was 49.9%. Our results show that 74% of the participants who experienced falls had postfall injuries. Old participants

Full Text available with Trip Pro

2018 BMJ open

29. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. (PubMed)

compared with pre-eclampsia in a single pregnancy followed by normal subsequent pregnancy.Embase and Medline were searched until June 2017.All relevant studies on the risk of developing hypertension, atherosclerosis, ischaemic heart disease, cerebrovascular accident (CVA), thromboembolism, heart failure or overall hospitalisation and mortality due to CVD after having had recurrent pre-eclampsia.Twenty-two studies were included in the review. When possible, we calculated pooled risk ratios (RR) with 95 (...) Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. Women with a history of hypertensive disorders, including pre-eclampsia, during pregnancy have a two- to-five-fold increased risk of cardiovascular disease (CVD). In 15% of women, pre-eclampsia recurs in the following pregnancy.To evaluate all evidence on the future risk of developing hypertension and CVD after multiple pregnancies complicated by pre-eclampsia

2018 BJOG

30. Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer

nervous system disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA), or subarachnoid hemorrhage within six months of study entry. Baseline neuropathy > grade 2 Subjects with a known history of immunogenic response or allergic reactions attributed to compounds of similar chemical composition to dolastatin or auristatin Abnormal cardiac function, defined (...) Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2018 Clinical Trials

31. Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

. Current symptomatic congestive heart failure (New York Heart Association > class II), unstable cardiac arrhythmia requiring therapy (e.g. medication or pacemaker), unstable angina (e.g. new, worsening or persistent chest discomfort), or uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100mmHg). Or any of the following occurring within 6 months (180 days) prior to first dose of study drugs: Myocardial infarction, coronary/peripheral artery bypass graft, cerebrovascular accident (...) Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2018 Clinical Trials

32. Cardiovascular Disease Prevention in Women: Evidence-Based Guidelines For

screening with high-sensitivity C-reactive protein (hsCRP), which would be required for use of the Reynolds risk score, because there are no data to support the association between a reduction in hsCRP and improved clinical outcomes. Numerous other Table 2. Classi?cation of CVD Risk in Women Risk Status Criteria High risk (1 high-risk states) Clinically manifest CHD Clinically manifest cerebrovascular disease Clinically manifest peripheral arterial disease Abdominal aortic aneurysm End-stage or chronic (...) risk factors and the other half to treatment of CHD including secondary preventive therapies (4). Major randomized controlled clini- cal trials such as the Women’s Health Initiative have changed the practice of CVD prevention in women over the past decade (5). The investment in combating this major public health issue for women has been signi?cant, as have the scienti?c and medical achievements. Despite the gains that have been made, considerable challenges remain. In 2007, CVD still caused 1 death

2011 American College of Cardiology

33. anti10a Levels in Women Treated With LMWH in the Postpartum Period

Thromboembolism Drug: clexane (LMWH) Phase 4 Detailed Description: pregnancy and postpartum period are associated with increased risk of thromboembolism. this risk is further increased in women with thrombophilia. This risk is higher in the postpartum period compared with pregnancy period, especially the risk for pulmonary embolism (PE). The American College Of Obstetrics and Gynecologists, The American college of chest physicians and The Royal College of obstetricians and gynecologists recommend using low (...) molecular weight heparin during the postpartum period in women with thrombophilia and women with risk factor for developing thromboembolism. there is no specific guidelines regarding the best protocol based on the level of anti-10 a. This study will compare between two protocols based on anti-10a levels. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 116 participants Allocation: Randomized Intervention Model: Parallel Assignment

2016 Clinical Trials

34. Effect of Tibet Rhodiola Capsule on Hypoxia and Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea

(GFR<30ml/min), moderate and severe chronic obstructive pulmonary disease, and pulmonary arterial hypertension; Patients with malignant tumors, lymphoma and neuropsychiatric disorders; Patients with major surgery or trauma within 3 months, and active bleeding or cerebrovascular accident within 6 months; History of anemia (hemoglobin<90g/L) or thrombocytopenia (thrombocyte <90×10^9/L); Breastfeeding, pregnant, or potentially fertile women; Patients who have known to be allergic to Tibet Rhodiola (...) Effect of Tibet Rhodiola Capsule on Hypoxia and Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea Effect of Tibet Rhodiola Capsule on Hypoxia and Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

35. A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

function criteria: Current unstable arrhythmia requiring treatment. History of symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or IV). History of myocardial infarction, pulmonary embolism or cerebrovascular accident within 6 months of enrollment. Current unstable angina. Prior treatment for MDS with HDAC inhibitors Zolinza (vorinostat), Belenodaq (belinostat), Farydak (panobinostat), Istodax (romidepsin/depsipetide), or investigational agent with significant action (...) A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

36. Cardiovascular risk assessment by FRS and SCORE in Iranian adult population (PubMed)

average 10-year risk of coronary artery disease (FRS) and 10-year risk of fatal coronary and cerebrovascular accidents (SCORE) in the 25 to 64 year-old population was 13.82 and 0.72 respectively. The relative frequency of the intermediate- and high- risk subjects was 25.8 and 22.6% based on FRS and 9.2 and 1.8% based on SCORE respectively. Average FRS and SCORE were significantly higher among men than women, but were not significantly different among urban and rural residents.A significant proportion (...) Cardiovascular risk assessment by FRS and SCORE in Iranian adult population Handling the growing epidemic of coronary heart disease in developing nations hinges on primary prevention, which logistically requires directing preventive interventions to those at the highest risk. Therefore, implementing cardiovascular risk assessment profiles is crucial to distinguish high risk groups who truly need extensive preventive measures. We aimed to draw a picture of the cardiovascular risk profiles

Full Text available with Trip Pro

2017 Journal of diabetes and metabolic disorders

37. CD4 Count in HIV- Brain Dead Donors: Insight into Donor Risk Assessment for HIV+ donors. (PubMed)

200 cells/μL; however, the numbers of circulating CD4+ cells in the HIV-negative (HIV-) brain-dead donor (BDD) is not known.Circulating T-lymphocyte subset profiles in conventional HIV- BDD were measured in 20 BDD in a clinical laboratory.The mean age of the BDD cohort was 48.7 years, 95% were white and 45% were women. The average body mass index was 29.2 kg/m. Cerebrovascular accident (40%) was the most prevalent cause of death. Sixteen (80%) subjects had a CD4 count ≤441 cells/μL (lower limit (...) CD4 Count in HIV- Brain Dead Donors: Insight into Donor Risk Assessment for HIV+ donors. The Human Immunodeficiency Virus (HIV) Organ Policy Equity Act allows for transplantation of organs from HIV-infected individuals (HIV+), provided it is performed under a research protocol. The safety assessment of an organ for transplantation is an essential element of the donation process. The risk for HIV-associated opportunistic infections increases as circulating CD4+ lymphocytes decrease to less than

2016 Transplantation

38. Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

stenosis, cerebrovascular accident, transient ischemic attack, severe peripheral vascular disease, or disseminated intravascular coagulation within 3 months of enrollment. Patients with a known congenital bleeding disorder. Patients with a known antiphospholipid antibody syndrome. Patients with present or past specific factor inhibitor activity. Patients with thrombocytopenia of <80,000/μL or history of heparin-induced thrombocytopenia. Patients who have received heparin of any type or any non-VKA (...) Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk. Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk. - Full Text View

2016 Clinical Trials

39. Effect of Gender on the Risk of Neurologic Events and Subsequent Outcomes in Patients With Left Ventricular Assist Devices. (PubMed)

neurologic event on all-cause mortality by gender. Our study included 34 women and 157 men who received a HeartMate II LVAD at the University of Rochester Medical Center, Rochester, New York, from May 5, 2008, to June 5, 2014. Neurologic event was defined as a transient ischemic attack or cerebrovascular accident (hemorrhagic or ischemic). During a median follow-up of 25 months, 16 women (47%) and 20 men (13%) had neurologic events. Among patients with neurologic events, 7 women (44%) and 9 men (45 (...) Effect of Gender on the Risk of Neurologic Events and Subsequent Outcomes in Patients With Left Ventricular Assist Devices. Previous studies have shown that women with continuous-flow left ventricular assist devices (LVADs) are at greater risk of neurologic events. However, the relation between neurologic events and subsequent outcomes by gender is not well understood. We aimed to identify gender differences in the risk of neurologic events in patients with LVAD and the impact of time-dependent

2016 American Journal of Cardiology

40. Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients

Posted : August 30, 2017 Sponsor: Stanford University Information provided by (Responsible Party): Greg Zaharchuk, Stanford University Study Details Study Description Go to Brief Summary: Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya disease and stroke patients Condition or disease Intervention/treatment Phase Cerebrovascular Accident Moyamoya Disease Drug: Xenon contrast agent Device: Magnetic Resonance Imaging Not Applicable Detailed Description: In the early hours following (...) and non-pregnant women, at least 21 years of age. Patients admitted to the inpatient Stanford Stroke Service for stroke-like symptoms, less than 24 hours from last time seen normal. Ability to comply with all studies. Clinical Patient Acetazolamide MRI Inclusion Criteria: Men and non-pregnant women, at least 21 years of age. Patients admitted to the inpatient Stanford Stroke Service or Neurosurgical -Service for symptoms compatible with cerebrovascular disease. Ability to comply with all studies

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>